抗人IL18BP/IL18BPa鼠单抗
产品名称: 抗人IL18BP/IL18BPa鼠单抗
英文名称: IL18BPa IL18BPa IL-18BPa
产品编号: 10357-MM01
产品价格: null
产品产地: 北京
品牌商标: 义翘神州(SinoBiologi
更新时间: null
使用范围: western blot
- 联系人 :
- 地址 : 北京亦庄东区科创十街18号院9号楼306室
- 邮编 : 100176
- 所在区域 : 北京
- 电话 : 点击查看
- 传真 : 点击查看
- 邮箱 : marketing@sinobiological.cn
官方网址:http://www.sinobiological.cn/IL-18BP-Antibody-g-1487.html
Interleukin 18 Binding Protein ( IL18BPa ) Antibody
IL18BPa抗体产品信息
Immunogen: Recombinant human IL18BP protein ( Catalog#10357-H08H )
Clone ID:
9A2D4E11
Ig Type: Mouse IgG1
缓冲液: 0.2 μm filtered solution in PBS with 5% trehalose Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, human cell-derived, recombinant human IL18BPa N-terminal domain ( rhIL18BPa; Catalog#10357-H08H; NP_001034748.1; Met 1- Gly 192 ). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
IL18BPa抗体使用指南
Specificity: Human IL18BP / IL18BPa
No cross-reactivity with human cell lysate ( 293 cell line ) in WB and ELISA.
Western blot : This antibody can be used at 1 - 2 ug/mL with the appropriate secondary reagents to detect human IL18BPa in WB. Using a DAB detection system, the detection limit for human IL18BPa is approximately 20ng/lane under non-reducing conditions and reduced conditions. 储存方法: This antibody can be stored at 2℃-8℃ for 1 month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.IL18BP Antibody Related Products & Topics
相关研究领域:
Immunology>>Cytokine & Receptor>>Interleukin & Receptor >>IL-1 superfamily and IL-1R/TLR family >>IL-18BP
蛋白:
Molecule Species Description //For Detailed Info.------CLICK! Cat No IL-18BP Mouse IL-18BP Protein, Recombinant 50206-M08H IL-18BPa Human IL-18BPa/Fc Protein, Recombinant 10357-H03H IL-18BPa Human IL-18BPa Protein, Recombinant 10357-H08H 抗体:
Molecule Application Description //For Detailed Info.------CLICK! Cat No Mouse
IL-18BPELISA Rabbit Polyclonal Antibody 50206-RP01 Mouse
IL-18BPWB, ELISA Rabbit Polyclonal Antibody (Antigen Affinity Purified) 50206-RP02 Human
IL-18BPaWB Mouse Monoclonal Antibody 10357-MM01 Human
IL-18BPaELISA Mouse Monoclonal Antibody 10357-MM02 Human
IL-18BPaELISA Rabbit Polyclonal Antibody 10357-RP03 Human
IL-18BPaWB, ELISA Rabbit Polyclonal Antibody (Antigen Affinity Purified) 10357-RP04 IL18BPa Antibody Background
Interleukin 18 binding protein (IL18BP) is a secreted glycoprotein which antagonizes the activity of the proinflammatory cytokine IL18 by binding to IL18 and blocking its biological activity. At least four isoforms differing in affinity for IL18 are produced from alternative splicing, and IL18 BP isoform a contains one immunoglobulin (Ig)-like C2-type domain. IL18BPa binds IL18 with high affinity, prevents the binding of IL18 to its receptor, and inhibits the production of IFN- gamma, IL8, and activationof NF-kappa B, resulting in reduced T- helper type 1 (Th1) immune responses. IL18BPa is constitutively expressed and secreted in mononuclear cells, and its expression can be induced and enhanced through the IFN- gamma-mediated pathway.The identified IFN-γ/IL18BPa negative feedback loop probably plays a key role in the modulation of both innate and adaptive immunity. A severe IL18/IL18BP imbalance is associated with hemophagocytic syndrome (HPS) characterized by an uncontrolled activation of Th1 lymphocytes and macrophages. In addition, IL18BPa is suggested to has a possible antimetastatic benefit, since IL18 plays a significant role in tumor hepatic metastasis.
参考文献
1. Aizawa, Y. et al., 1999, FEBS. Lett. 445: 338-342.
2. Kim, S.H. et al., 2000. Proc. Natl. Acad. Sci. USA 97: 1190-1195.
3. Veenstra, K.G. et al., 2002, J. Immunol. 168: 2282-2287.
4. Mazodier, K. et al., 2005, Blood. 106: 3483-3489.
5. Carrascal, M.T. et al., 2003, Cancer. Res. 63: 491-497.